No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission.

Dipartimento Ematologia e Oncologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) G. Gaslini, Largo G. Gaslini 5, Genoa, Italy.
Blood (Impact Factor: 9.78). 12/2011; 118(25):6683-90. DOI: 10.1182/blood-2011-05-354233
Source: PubMed

ABSTRACT Acute lymphoblastic leukemia (ALL) in second complete remission is one of the most common indications for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients. We compared the outcome after HCST of adolescents, aged 14 to 18 years, with that of children (ie, patients < 14 years of age). Enrolled in the study were 395 patients given the allograft between January 1990 and December 2007; both children (334) and adolescents (61) were transplanted in the same pediatric institutions. All patients received a myeloablative regimen that included total body irradiation in the majority of them. The donor was an HLA-identical sibling for 199 patients and an unrelated volunteer in the remaining 196 patients. Children and adolescents had a comparable cumulative incidence of transplantation-related mortality, disease recurrence, and of both acute and chronic graft-versus-host disease. The 10-year probability of overall survival and event-free survival for the whole cohort of patients were 57% (95% confidence interval, 52%-62%) and 54% (95% confidence interval, 49%-59%), respectively, with no difference between children and adolescents. This study documents that adolescents with ALL in second complete remission given HSCT in pediatric centers have an outcome that does not differ from that of patients younger than 14 years of age.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Although most children with ALL can be cured by chemotherapy approaches, allogeneic hematopoietic cell transplant (HCT) therapy offers a better chance of cure to selected high-risk patients in first remission and most children who relapse. Although transplant-related mortality has decreased significantly in the past decade, relapse remains high after HCT for ALL; developing strategies to decrease relapse and improve survival are vital. Recent studies have shown that relapse risk can be accurately defined using measurements of minimal residual disease (MRD) both pre- and post-HCT and by knowing whether patients get GVHD in the first 2 months after transplant. With these risk definitions in hand, investigators are now applying novel agents and immunotherapeutic methods in attempt to lower MRD before transplant and modulate the GVL effect after transplant. With powerful new immunological approaches coming on line, the transplant process itself will likely expand to include pre and/or post-HCT interventions aimed at reducing relapse.Bone Marrow Transplantation advance online publication, 16 June 2014; doi:10.1038/bmt.2014.114.
    Bone Marrow Transplantation 06/2014; DOI:10.1038/bmt.2014.114 · 3.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Conventional myeloablative conditioning (MAC) regimens often cause severe regimen-related toxicity (RRT). Furthermore, many patients suffer from poor quality of life in accordance with the increase in long-term survivors. We therefore devised a reduced-toxicity myeloablative conditioning (RTMAC) regimen consisting of 8-Gy total body irradiation (TBI), fludarabine (FLU) and cyclophosphamide (CY) for pediatric hematological malignancies. A retrospective single-center analysis was performed on patients with leukemia or myelodysplastic syndrome (MDS), aged ≤20 years, who had received an 8-Gy TBI/FLU/CY RTMAC regimen followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thirty-one patients underwent first allo-HSCT after an RTMAC regimen. The diagnoses were acute lymphoblastic leukemia (n = 11), acute myeloid leukemia (n = 13), MDS (n = 4), juvenile myelomonocytic leukemia (n = 1) and acute leukemias of ambiguous lineage (n = 2). While 3 patients showed early hematological relapse, the remaining 28 patients achieved engraftments. None of the patients developed grade 4 or 5 toxicities during the study period. The 5-year overall survival and relapse-free survival were 80% [95% confidence interval: CI, 61-91%] and 71% [95% CI, 52-84%], respectively. Our RTMAC regimen would be less toxic and offers a high probability of survival for children with hematological malignancies.
    Scientific Reports 11/2014; 4:6942. DOI:10.1038/srep06942 · 5.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sirolimus, an mTOR inhibitor, has activity against human ALL in xenograft models and efficacy in preventing acute GVHD (aGVHD). We tested whether addition of sirolimus to GVHD prophylaxis of children undergoing transplantation for ALL would decrease aGVHD and relapse, thus improving survival. Patients were randomized to tacrolimus/methotrexate (standard) or tacrolimus/methotrexate/sirolimus (experimental). The study met futility rules for survival after enrolling 146 of 259 planned patients. The proportion of patients with Grade II-IV aGVHD was 31% vs. 18% in the standard vs. the experimental arm (p=0.04), however, grade III-IV aGVHD was not statistically different (13% vs. 10%, p=0.28). Rates of veno-occlusive disease and thrombotic microangiopathy were lower in the non-sirolimus arm (9% vs. 21% VOD, p=0.05; 1% vs. 10% TMA, p=0.06). At 2 years, EFS and OS were 56% vs 46%, and 65% vs 55% in the standard and experimental arms, respectively (p= 0.28 and 0.23). Multivariate analysis showed increased relapse risk in children with ≥0.1% MRD pre-transplant, and decreased risk in patients with grades I-III aGVHD (p=0.04). Grades I-III aGVHD were associated with improved EFS (p=0.02), while grade IV aGVHD and extramedullary disease at initial diagnosis led to inferior OS. Although addition of sirolimus decreased aGVHD, survival was not improved. The study is registered with ( Identifier: NCT00382109).
    Blood 02/2014; DOI:10.1182/blood-2013-10-534297 · 9.78 Impact Factor